Pyxis Oncology News and Activities

Pyxis Oncology is a company listed under the stock ticker PYXS (US).

View the org chart displaying its 26 main executives

Most searched biographies at Pyxis Oncology

• Thomas Civik, Interim Chief Executive Officer
• Rachel Humphrey, Director
• John Flavin, Chairman and Independent Director

Popular executive movements at Pyxis Oncology

• Stephen Worsley, Senior Vice President and Chief Business Officer, has left the company  (posted on May 8 2026).
• Frank Wang, who was Head, Nonclinical Operations, is promoted to Vice President of Toxicology  (posted on May 8 2026).
• Breana Loreaux, who was Manager, Chemistry, Manufacturing, Controls and Technical Operations, is promoted to Senior Manager, Chemistry, Manufacturing, Controls and Technical Operations  (posted on May 8 2026).

Click here to view some more movements at Pyxis Oncology

Create your alert
to follow the executive moves at Pyxis Oncology.

Pyxis Oncology has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Pyxis Oncology

• Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data | Pyxis Oncology
• Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 | Pyxis Oncology
• Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 | Pyxis Oncology
• Pyxis Oncology to Participate in Two Upcoming Investor Conferences | Pyxis Oncology
• Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 | Pyxis Oncology
• Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference | Pyxis Oncology
• Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference | Pyxis Oncology
• Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Pyxis Oncology
• Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger | Pyxis Oncology
• Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference | Pyxis Oncology
• View more press releases Close

Social media about Pyxis Oncology

• Pyxis Oncology on Wikipedia, Google News & Yahoo Finance
• Pyxis Oncology on LinkedIn, X (Twitter) & YouTube